Loading…
Sterne, Kessler, Goldstein & Fox P.L.L.C.
Manufacturing-IP focusActive litigationYour innovations are worth the best protection
Patent portfolio & lifecycle
5 familiesIllustrative families — lifecycle & valuation, deterministic
Extended-release dosing regimen
Small molecules
GrantedStandard · 51
Dosing regimen · National phase · USPTO
Filed 2014 · granted 2018 · expires 2029
Glycosylation-optimized biologic composition
Confidential · Biologics
OpposedStrong · 57
Composition of matter · National phase · USPTO / EPO
Filed 2013 · granted 2017 · expires 2033
Sterile depot injectable formulation
Confidential · Sterile injectables
GrantedStrong · 59
Formulation · National phase · USPTO
Filed 2015 · granted 2019 · expires 2035
mRNA-LNP composition
Confidential · mRNA / LNP
GrantedCore asset · 79
Composition of matter · PCT · USPTO / EPO / JPO
Filed 2017 · granted 2021 · expires 2037
Claim 1: A composition comprising a modified-nucleoside mRNA encapsulated in an ionizable lipid nanoparticle with defined lipid molar ratios.
Biosimilar manufacturing cell-line process
Biosimilars
PendingStandard · 51
Manufacturing process · PCT · USPTO
Filed 2020 · expires 2040
SK
Sterne, Kessler, Goldstein & Fox P.L.L.C.
IP & patent counsel · United States
Live record · illustrative seed data · scores deterministic, rules-based — not AI.